AbbVie’s Humira Succession Plan Begins Taking Shape With Skyrizi US Approval
Executive Summary
Central to AbbVie’s plans to endure biosimilar erosion to Humira, Skyrizi gets US approval in psoriasis, with approval of upadacitinib expected in RA this year.